Researchers at Children’s Hospital of Philadelphia (CHOP) identified a potential new treatment pathway for mitral valve disease, a progressive condition in which the heart’s mitral valve (the left atrial-ventricular valve) weakens and allows blood to leak backward. Reported in Cardiovascular Research, the findings could inform future precision treatments for mitral valve disease and related heart conditions.
The condition can cause shortness of breath, fatigue, irregular heartbeats, and heart failure. Many people with advanced mitral valve disease require surgery to repair or replace the valve, and no medications have been proven to halt its progression.
Robert J. Levy, MD, William J. Rashkind Endowed Chair in Pediatric Cardiology in CHOP’s Cardiac Center and senior study author, said the study, led by Stanley J. Stachelek, PhD, Research Associate Professor in CHOP’s Cardiac Center, builds on more than 20 years of research into serotonin’s role in heart valve disease. Dr. Levy’s earlier work showed that serotonin, a chemical messenger in the body, can contribute to valve damage. The new research points to another possible factor – PIEZO1 and PIEZO2 proteins that help cells sense physical forces – which may explain how the stress of each heartbeat contributes to disease.
“Our findings show a new connection between the effects of physical forces of each heartbeat on a diseased mitral valve, serotonin signaling, and the buildup of collagen that can further stiffen the mitral valve,” said Stachelek. “This could point to new treatment approaches that target PIEZO1, PIEZO2, or serotonin-related pathways to help slow the progression of mitral regurgitation.”
In the study, researchers found PIEZO1 and PIEZO2 in both healthy and diseased human mitral valve tissue. These proteins were abundantly present in valve interstitial cells, the cells that make up most of the mitral valve and help maintain its structure. The researchers also found proteins involved in serotonin signaling in these cells, suggesting that physical forces and chemical signals may work together in the progression of valve disease.
In laboratory experiments, increasing the activity of PIEZO1 increased calcium activity in valve cells and caused them to make more serotonin and proteins, including collagen. Repeatedly stretching the cells to mimic the motion of a heart valve leaflet also increased serotonin production and collagen buildup. Reducing the activity of PIEZO1 or PIEZO2 limited some of these effects, suggesting these force-sensing proteins may help drive the thickening and stiffening of the valve seen in mitral valve disease.
Levy said the research is ongoing with the goal of determining whether these findings can lead to safe and effective medicines that could one day help slow the progression of mitral regurgitation and delay or prevent the need for surgery.
This work was supported by National Institutes of Health grants (R01HL131872) and (R01HL131872-S1), (T32HL007915), (U54HL165442) and (R01HL178026); American Heart Association awards (960273) and (25PBA1513942); and funding from the Erin Beatty Fund (CHOP), Kibel Fund (CHOP), Valley Hospital Foundation “Marjorie C. Bunnel” Charitable Fund, William J. Rashkind Endowment (CHOP) and a CHOP Cardiac Center Innovation Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Stachelek et al. “Mechanosensing channels PIEZO1 and PIEZO2 regulate mitral valve serotonin-mediated homeostasis and pathophysiology.” Cardiovascular Research. September 3, 2026. DOI: 10.1093/cvr/cvag190/8780908.
Featured in this article
Experts
Specialties & Programs
Researchers at Children’s Hospital of Philadelphia (CHOP) identified a potential new treatment pathway for mitral valve disease, a progressive condition in which the heart’s mitral valve (the left atrial-ventricular valve) weakens and allows blood to leak backward. Reported in Cardiovascular Research, the findings could inform future precision treatments for mitral valve disease and related heart conditions.
The condition can cause shortness of breath, fatigue, irregular heartbeats, and heart failure. Many people with advanced mitral valve disease require surgery to repair or replace the valve, and no medications have been proven to halt its progression.
Robert J. Levy, MD, William J. Rashkind Endowed Chair in Pediatric Cardiology in CHOP’s Cardiac Center and senior study author, said the study, led by Stanley J. Stachelek, PhD, Research Associate Professor in CHOP’s Cardiac Center, builds on more than 20 years of research into serotonin’s role in heart valve disease. Dr. Levy’s earlier work showed that serotonin, a chemical messenger in the body, can contribute to valve damage. The new research points to another possible factor – PIEZO1 and PIEZO2 proteins that help cells sense physical forces – which may explain how the stress of each heartbeat contributes to disease.
“Our findings show a new connection between the effects of physical forces of each heartbeat on a diseased mitral valve, serotonin signaling, and the buildup of collagen that can further stiffen the mitral valve,” said Stachelek. “This could point to new treatment approaches that target PIEZO1, PIEZO2, or serotonin-related pathways to help slow the progression of mitral regurgitation.”
In the study, researchers found PIEZO1 and PIEZO2 in both healthy and diseased human mitral valve tissue. These proteins were abundantly present in valve interstitial cells, the cells that make up most of the mitral valve and help maintain its structure. The researchers also found proteins involved in serotonin signaling in these cells, suggesting that physical forces and chemical signals may work together in the progression of valve disease.
In laboratory experiments, increasing the activity of PIEZO1 increased calcium activity in valve cells and caused them to make more serotonin and proteins, including collagen. Repeatedly stretching the cells to mimic the motion of a heart valve leaflet also increased serotonin production and collagen buildup. Reducing the activity of PIEZO1 or PIEZO2 limited some of these effects, suggesting these force-sensing proteins may help drive the thickening and stiffening of the valve seen in mitral valve disease.
Levy said the research is ongoing with the goal of determining whether these findings can lead to safe and effective medicines that could one day help slow the progression of mitral regurgitation and delay or prevent the need for surgery.
This work was supported by National Institutes of Health grants (R01HL131872) and (R01HL131872-S1), (T32HL007915), (U54HL165442) and (R01HL178026); American Heart Association awards (960273) and (25PBA1513942); and funding from the Erin Beatty Fund (CHOP), Kibel Fund (CHOP), Valley Hospital Foundation “Marjorie C. Bunnel” Charitable Fund, William J. Rashkind Endowment (CHOP) and a CHOP Cardiac Center Innovation Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Stachelek et al. “Mechanosensing channels PIEZO1 and PIEZO2 regulate mitral valve serotonin-mediated homeostasis and pathophysiology.” Cardiovascular Research. September 3, 2026. DOI: 10.1093/cvr/cvag190/8780908.
Contact us
Natalie Solimeo
Cardiac Center